Cargando…
Safety evaluation of the canine osteosarcoma vaccine, live Listeria vector
Canine osteosarcoma (OSA) is an aggressive bone tumour in dogs. Standard‐of‐care treatment typically results in relatively short survival times; thus, alternative treatments are needed to confer a survival advantage. It has been shown that OSA is an immunogenic tumour, suggesting that immune modulat...
Autores principales: | Musser, Margaret L., Berger, Erika P., Tripp, Chelsea D., Clifford, Craig A., Bergman, Philip J., Johannes, Chad M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891610/ https://www.ncbi.nlm.nih.gov/pubmed/32729979 http://dx.doi.org/10.1111/vco.12642 |
Ejemplares similares
-
Vaccine strain Listeria monocytogenes abscess in a dog: a case report
por: Musser, Margaret L., et al.
Publicado: (2019) -
Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014–2017)
por: Musser, Margaret L., et al.
Publicado: (2018) -
Randomised trial evaluating chemotherapy alone or chemotherapy and a novel monoclonal antibody for canine T‐cell lymphoma: A multicentre US study
por: Musser, Margaret L., et al.
Publicado: (2022) -
Toceranib phosphate (Palladia) for the treatment of canine exocrine pancreatic adenocarcinoma
por: Musser, Margaret L., et al.
Publicado: (2021) -
Pilot safety evaluation of doxorubicin chemotherapy combined with non-specific immunotherapy (Immunocidin®) for canine splenic hemangiosarcoma
por: Musser, Margaret L., et al.
Publicado: (2022)